Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) Profit After Tax (2021 - 2025)

Prime Medicine's Profit After Tax history spans 5 years, with the latest figure at -$46.1 million for Q4 2025.

  • For Q4 2025, Profit After Tax fell 9.0% year-over-year to -$46.1 million; the TTM value through Dec 2025 reached -$201.1 million, down 2.69%, while the annual FY2025 figure was -$201.1 million, 2.69% down from the prior year.
  • Profit After Tax reached -$46.1 million in Q4 2025 per PRME's latest filing, up from -$50.6 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of -$16.4 million in Q3 2021 to a low of -$65.6 million in Q4 2023.
  • Average Profit After Tax over 5 years is -$44.2 million, with a median of -$45.9 million recorded in 2024.
  • The largest YoY upside for Profit After Tax was 37.56% in 2022 against a maximum downside of 78.83% in 2022.
  • A 5-year view of Profit After Tax shows it stood at -$62.9 million in 2021, then surged by 37.56% to -$39.3 million in 2022, then tumbled by 67.1% to -$65.6 million in 2023, then surged by 35.6% to -$42.3 million in 2024, then dropped by 9.0% to -$46.1 million in 2025.
  • Per Business Quant, the three most recent readings for PRME's Profit After Tax are -$46.1 million (Q4 2025), -$50.6 million (Q3 2025), and -$52.6 million (Q2 2025).